Lyra Therapeutics, Inc. (LYRA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lyra Therapeutics, Inc. (LYRA) trades at $0.44 with AI Score 49/100 (Grade C). Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for chronic rhinosinusitis (CRS). Market cap: $781,126, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for LYRA: LYRA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LYRA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LYRA: the 1 perspectives are evenly split.
How is this calculated? →Lyra Therapeutics, Inc. (LYRA) Healthcare & Pipeline Overview
Lyra Therapeutics, Inc. is a clinical-stage biotech firm specializing in sustained-release anti-inflammatory treatments for chronic rhinosinusitis, with lead candidates LYR-210 in Phase III trials and LYR-220 targeting patients needing further intervention, positioning them within the evolving drug delivery landscape.
What Is the Investment Thesis for LYRA?
Lyra Therapeutics presents a focused investment opportunity within the biotechnology sector, specifically targeting chronic rhinosinusitis (CRS). The primary value driver is the successful completion of Phase III clinical trials for LYR-210 and subsequent FDA approval, potentially addressing a significant unmet need in CRS treatment. The collaboration with LianBio for commercialization in Asia offers additional revenue streams and market expansion. Key metrics to monitor include clinical trial results, regulatory milestones, and partnership performance. The company's high negative profit margin of -7266.1% indicates a pre-revenue stage, making it a higher-risk, higher-reward investment. Upcoming catalysts include the release of Phase III trial data for LYR-210. Potential risks include clinical trial failures, regulatory setbacks, and competition from existing CRS treatments.
Based on FMP financials and quantitative analysis
LYRA Key Highlights
- LYR-210 is in Phase III clinical trials for the treatment of chronic rhinosinusitis (CRS).
- LYR-220 targets CRS patients who have failed previous medical management.
- Collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in key Asian markets.
- The company's technology delivers medicines directly to the affected tissue for sustained periods with a single administration.
- The company's profit margin is -7266.1%.
Who Are LYRA's Competitors?
LYRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LYRA's Key Strengths?
- Innovative drug delivery technology.
- Lead product candidate in Phase III clinical trials.
- Collaboration agreement with LianBio.
- Experienced management team.
What Are LYRA's Weaknesses?
- High negative profit margin.
- Limited commercialization experience.
- Reliance on successful clinical trial outcomes.
- Small number of employees.
What Could Drive LYRA Stock Higher?
- Release of Phase III clinical trial data for LYR-210.
- Potential FDA approval of LYR-210.
- Continued progress in the collaboration with LianBio.
- Development of LYR-220 for CRS patients who have failed previous medical management.
What Are the Key Risks for LYRA?
- Financial-distress signal — its Altman Z-Score of -19.16 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for LYR-210 or LYR-220.
- Regulatory setbacks in obtaining FDA approval.
- Competition from existing CRS treatments.
- High cash burn rate due to ongoing clinical trials and research and development expenses.
- Dependence on successful commercialization of LYR-210 to generate revenue.
What Are the Growth Opportunities for LYRA?
- Expansion into new therapeutic areas: Lyra Therapeutics can leverage its drug delivery technology to target other inflammatory conditions beyond chronic rhinosinusitis (CRS), such as allergic rhinitis or nasal polyps. This would involve developing new formulations and conducting clinical trials to demonstrate efficacy in these additional indications. The market for allergic rhinitis treatments, for example, is estimated to be worth billions of dollars globally, offering a significant growth opportunity. Timeline: 3-5 years.
- Geographic expansion: While Lyra has a collaboration with LianBio for certain Asian markets, there are opportunities to expand into other regions, such as Europe and Latin America. This could involve establishing partnerships with local pharmaceutical companies or building a direct sales force. The European market for CRS treatments is particularly attractive due to its large population and well-developed healthcare infrastructure. Timeline: 2-4 years.
- Development of next-generation drug delivery systems: Lyra can invest in research and development to create more advanced drug delivery systems that offer even longer-lasting or more targeted medication release. This could involve using biodegradable materials or incorporating smart technologies that respond to changes in the sinonasal environment. Such innovations would enhance the company's competitive advantage and attract further investment. Timeline: 5+ years.
- Acquisition or licensing of complementary technologies: Lyra could acquire or license technologies that complement its existing drug delivery platform, such as novel anti-inflammatory compounds or diagnostic tools for CRS. This would broaden the company's product pipeline and create synergies between different therapeutic approaches. For example, acquiring a company with a promising new anti-inflammatory molecule could accelerate the development of new CRS treatments. Timeline: 1-3 years.
- Personalized medicine approach: Lyra can explore the use of biomarkers to identify patients who are most likely to respond to its therapies. This would involve conducting research to identify genetic or molecular markers that predict treatment outcomes. By tailoring treatment to individual patients, Lyra could improve efficacy and reduce the risk of adverse events. This personalized medicine approach would also differentiate Lyra from competitors offering one-size-fits-all treatments. Timeline: 3-5 years.
What Opportunities Does LYRA Have?
- Expansion into new therapeutic areas.
- Geographic expansion into Europe and Latin America.
- Development of next-generation drug delivery systems.
- Acquisition or licensing of complementary technologies.
What Threats Does LYRA Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from existing CRS treatments.
- Patent infringement lawsuits.
What Are LYRA's Competitive Advantages?
- Proprietary drug delivery technology that provides sustained medication release.
- Strong patent protection for its product candidates and delivery systems.
- Clinical data demonstrating the efficacy and safety of its therapies.
- Established partnerships with leading pharmaceutical companies.
What Does LYRA Do?
Lyra Therapeutics, Inc., founded in 2005 and headquartered in Watertown, Massachusetts, is a clinical-stage biotechnology company dedicated to transforming the treatment of chronic rhinosinusitis (CRS). Originally incorporated as 480 Biomedical, Inc., the company rebranded as Lyra Therapeutics in July 2018 to better reflect its focus on innovative therapeutic solutions for CRS. Lyra's core technology centers around developing implantable drug matrices designed to deliver medication directly to the sinonasal tissues for extended periods following a single administration. This approach aims to improve patient outcomes by providing consistent drug exposure while reducing the need for frequent interventions. The company's lead product candidate, LYR-210, is an anti-inflammatory implant currently in Phase III clinical trials for CRS. LYR-220 is another product candidate targeting CRS patients who have not responded adequately to previous medical treatments and require ongoing symptom management. Lyra has also established a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in key Asian markets, including mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand, expanding its potential geographic reach. With a focus on localized drug delivery and a pipeline targeting unmet needs in CRS treatment, Lyra Therapeutics seeks to establish itself as a leader in innovative sinonasal therapies.
What Products and Services Does LYRA Offer?
- Develops anti-inflammatory therapies for chronic rhinosinusitis (CRS).
- Creates implantable drug matrices for sustained drug delivery.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approval for its therapies from agencies like the FDA.
- Collaborates with other companies to commercialize its products in different regions.
- Focuses on localized drug delivery to the sinonasal tissues.
How Does LYRA Make Money?
- Develops and patents novel drug delivery systems for CRS.
- Out-licenses or partners to commercialize its products in specific territories.
- Generates revenue through milestone payments, royalties, and product sales.
- Focuses on research and development to expand its product pipeline.
What Industry Does LYRA Operate In?
Lyra Therapeutics operates within the biotechnology industry, focusing on developing treatments for chronic rhinosinusitis (CRS). The market for CRS treatments is substantial, driven by the high prevalence of the condition and the limitations of existing therapies. The competitive landscape includes established pharmaceutical companies offering nasal sprays and surgical interventions. Lyra's innovative drug delivery technology, which provides sustained medication release directly to the sinonasal tissues, differentiates it from traditional approaches. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition.
Who Are LYRA's Key Customers?
- Patients suffering from chronic rhinosinusitis (CRS).
- ENT (ear, nose, and throat) physicians who treat CRS patients.
- Hospitals and clinics that offer CRS treatments.
- Pharmaceutical companies that partner with Lyra to commercialize its products.
How Lyra Therapeutics, Inc. Is Valued
Lyra Therapeutics, Inc. carries a market capitalization of 781K, placing it in the micro-cap category. Relative to its peer group, LYRA's quantitative score of 49/100 is below the peer average of 76/100.
Key Financial Metrics
Return on assets is -80.1%, showing how much profit it generates from its asset base. A current ratio of 1.71 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 3/9Financial Health
Lyra Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.16 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Lyra Therapeutics, Inc. revenue of about $2.7M for fiscal 2026, with EPS near $-0.99.
Net sellingInsider Activity
Over the past six months, Lyra Therapeutics, Inc. insiders filed 3 SEC Form 4 transactions — 3 sales and 0 purchases. On net that is roughly 3K shares disposed (about $0), a signal worth weighing alongside the fundamentals.
LYRA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Lyra's recent insider buying suggests confidence from those closest to the company's operations. It's like when Elon Musk bought Tesla shares in 2019, signaling belief in the company's future.
- Positive community sentiment indicates growing belief in Lyra's technology and market potential; similar to the early buzz around CRISPR stocks.
- The community sees potential for Lyra to disrupt the chronic rhinosinusitis treatment market, a view akin to how investors perceived Roku's potential in streaming.
- Lyra's focus on localized drug delivery is perceived as a significant advantage, reflecting a belief in targeted therapies, much like the excitement around antibody-drug conjugates in oncology.
Bear Case
- Some community members express concerns about Lyra's ability to scale production efficiently, reminiscent of challenges faced by early electric vehicle manufacturers.
- There are worries about potential regulatory hurdles for Lyra's innovative drug delivery system, a concern similar to the initial skepticism faced by gene therapy companies.
- Bearish sentiment highlights competition from established players in the ENT space, a situation akin to smaller biotechs facing giants like Pfizer.
- Concerns exist within the community regarding Lyra's cash burn rate and the need for future funding, mirroring worries about liquidity that plagued many dot-com companies in the early 2000s.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LYRA Latest News
No recent news available for LYRA.
LYRA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LYRA.
Price Targets
Wall Street price target analysis for LYRA.
LYRA MoonshotScore
What does this score mean?
The MoonshotScore rates LYRA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carmichael S. Roberts Jr.
CEO
Carmichael S. Roberts Jr. is the CEO of Lyra Therapeutics, bringing extensive experience in healthcare and biotechnology. His background includes leadership roles in venture capital and entrepreneurial ventures, focusing on the development and commercialization of innovative medical technologies. He has a proven track record of guiding companies through clinical development, regulatory approval, and market launch. Roberts' expertise spans across various therapeutic areas, including drug delivery, diagnostics, and medical devices. His educational background includes advanced degrees in engineering and business, providing a strong foundation for his leadership in the biotechnology industry.
Track Record: Under Carmichael S. Roberts Jr.'s leadership, Lyra Therapeutics has advanced its lead product candidate, LYR-210, into Phase III clinical trials. He has also secured a collaboration agreement with LianBio to expand the company's reach into key Asian markets. Roberts has focused on strengthening the company's intellectual property portfolio and building a strong team to support its clinical and commercial objectives.
Common Questions About LYRA (Healthcare)
What does Lyra Therapeutics, Inc. do?
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for chronic rhinosinusitis (CRS). Its core technology involves implantable drug matrices designed to deliver anti-inflammatory medication directly to the sinonasal tissues for sustained periods. The company's lead product candidate, LYR-210, is currently in Phase III clinical trials for CRS, and LYR-220 is being developed for patients who have not responded adequately to previous treatments. Lyra aims to provide improved treatment options for CRS patients through localized and sustained drug delivery.
What do analysts say about LYRA stock?
Given Lyra Therapeutics' clinical-stage status, analyst opinions are largely based on the potential success of LYR-210 and LYR-220. Key valuation metrics include projected peak sales, market penetration rates, and the likelihood of regulatory approval. Analyst consensus typically reflects a range of potential outcomes, from successful commercialization and significant revenue growth to clinical trial failures and financial challenges. Investors should carefully consider the risks and uncertainties associated with biotechnology companies in the clinical development phase. The company's beta of 0.30 suggests lower volatility compared to the overall market.
What are the main risks for LYRA?
The primary risks for Lyra Therapeutics include the potential failure of LYR-210 or LYR-220 in clinical trials, which would significantly impact the company's value. Regulatory setbacks in obtaining FDA approval also pose a significant risk. Competition from existing CRS treatments, such as nasal sprays and surgical interventions, could limit market share. Additionally, the company faces financial risks due to its high cash burn rate and dependence on successful commercialization to generate revenue. Intellectual property risks and potential patent infringement lawsuits are also relevant considerations.
What are the key factors to evaluate for LYRA?
Lyra Therapeutics, Inc. (LYRA) holds an AI score of 49/100 (low). Not financial advice.
How frequently does LYRA data refresh on this page?
LYRA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LYRA's recent stock price performance?
Lyra Therapeutics, Inc. (LYRA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LYRA overvalued or undervalued right now?
Valuing Lyra Therapeutics, Inc. (LYRA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LYRA?
Before investing in Lyra Therapeutics, Inc. (LYRA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Financial projections are based on assumptions and may not be accurate.